Highnoon Laboratories Limited · PSX:HINOON
Highnoon Laboratories — Investor Presentation (April 2024)
32 slides from Highnoon Laboratories's investor presentation, April 2024
Slide 1: Highnoon
Highnoon
Slide 2: Enriching Life
Enriching Life We understand that enriching life is not merely an idea but a tangible mission that requires action. That's why we invest in initiatives that promote health and wellness, support education and lifelong learning, and foster cultural enrichment.
Slide 3: About The Company
About The Company —— v
Slide 4: Our Values
Our Aspiring ¢ Innovation Values * Passion
Slide 5: Our Values: Reliability, Integrity, Courage, Customer Focus
¢ Reliability ® ¢ Integrity % ¢ Courage ¢ Customer Focus ¢ Compassion e Perseverance
Slide 6: Macroeconomic Highlights 2023
Macroeconomic Highlights 2023 Pakistan economy attained a GDP Growth GDP Growth of 0.29% in FY 2023 vs Last year 2022 GDP Growth of 6.1%. Inflation has risen from 12.5 percent Higher Inflation in 2022 to 29 percent in 2023, with food inflation even higher The recent financial turmoil has led to Cred
Slide 7: Economic Highlights: Major 2023 Events
Economic Highlights: Major 2023 Events- The Morgan Stanley Capital International Emerging Market (MSCI-EM) Index declined by 1.0% Market capitalization during Jul-Mar The performance of of the Pakistan Stock FY2023, which is an major World stock Exchange (PSX) index of 24 emerging markets remained r
Slide 8: Highnoon Group Companies
Highnoon Group Companies Route Health @ Curexa N\oqeradly the best choice! ; Health Associated Company Tetesidiary Company
Slide 9: Enhancing Growth & Patient Reach
Enhancing Growth & Patient Reach 12th Out of 700 Pharmaceutical 3 Mfg. Facilities 2 Pharmaceuticals Cardiology Respiratory Companies 1 Nutraceutical Metabolic 21 Bn USD 75.8 Mn 5 Brands in Presence in Leading Therapeutic Segments Annual Revenue 1 Billion Club 52 K 42.4K 17% 1800+ Pharmacies Health C
Slide 10: Distinction in Commercial Proceedings
Distinction in Commercial Proceedings Ranked 12th PKR 21 Bn (USD 75.8 Mn) Pharmaceuticals 5 Year CAGR 17% 1800+ 5
Slide 11: Milestone
Slide 12: Forbes Asia
Forbes Asia Only pharmaceutical company from Pakistan that has made it to the Forbes Asia Best under a Billion list thrice.
Slide 13: Industry Ranking
Industry Ranking Fast Growing among Leading Pharmaceuticals *IQVIA MAT DEC 2023
Slide 14: Industry Ranking
Industry Ranking 10 NATs and 7 MNCs are growing with double digit TOP 10 MNCs &NATs Nationals Multi - Nationals
Slide 15: Product Segments
Product Segments ef Cardiology N Metabolic Gastroenterology, Musculoskeletal Q Ga Obstetrics & () es — ee — &2 eS Respiratory ‘@ Urology
Slide 16: Leading Segments Overview
Leading Segments Overview - where Highnoon is amongst Leaders … CARDIOMETABOLIC RESPIRATORY ANTI - INFECTIVES 6.4 BN 3.8 BN 4.6 BN BusinessPortfolio BusinessPortfolio BusinessPortfolio (USD 23.1 Mn) (USD 13.8 Mn) (USD 16.5Mn) Therapeutic segment contribution 5.0% 7.0% 3.0% Corporation Contribution 3
Slide 17: Leading Brands
Leading 1.4Bn 1.2 Bn 1.5 Bn 1.2 Bn 1 Bn (USD 5.3Mn) (USD 4.3Mn) (USD 5.5 Mn) (USD 4.3Mn) (USD 3.6 Mn) Brands TM Combivair® Ulsanic® (Ebastine) Kestine (Budesonide + FormoterolFumarate) Tagipmet (Sitagliptin + MetforminHCI) (Sucralfate) Cyrocin® (CiprofloxacinHCI) 810 Mn 667 Mn 693 Mn 635 Mn 782 Mn (
Slide 18: Top 5 Products
* Highnoon Combivair®200 (Budesonide + Formoterol Fumarate) 200mcg + 6mcg SO Retacape WP vghnoon Kestine’ basting) 10g sorinousries ‘Aeray Reet Medicine Ulsanic°’ (Sucraitate) Cyteprotectve agont. * Highnoon Cyrocin’ (Citroen) ) 2501 tont-coxtec tate * Highnoon Tagipmet™ [Sitagliptin + Metformin HCI
Slide 19: Collaborations
| Collaborations ib Zamalaya Cipla WN Hiotaings Z almirall WBF sairsuvishi tanabe Phar SINCE 1930 =e C) © Chiesi People and ideas for innovation in healthcare
Slide 20: Collaborations
Collaborations Cd ss eu>,—« |S sSTK ~~ Shaukat Khanum f Help International =| Help International Memorial Cancer Hospital Welfare Trust ' Welfare Trust : @ S CRESS otal ral JDL Fatmid Foundation e Red Crescent Society , Sundus Foundation
Slide 21: Renowned Collaborations
Renowned Collaborations i i Oc European , Weill Cornell Society of . A Hypertension | Medicine The Aga Khan The European Society Pakistan Endocrine Weare University of Hypertension of Japan Society (PSE) Pakistan Society of Interventional Cardiology King Abdul Aziz University Royal College of Physic
Slide 22: International Exports / Products Currently in Pipeline
International 215 Products Currently Exports 130 Products in Pipeline
Slide 23: Financials
Slide 24: Key Performance Indicators Growth & Profits
Key Performance Indicators Growth & Profits Sales Revenue Rs.19.4 Bn GOLY 23% Total Assets Rs.14.025 Bn GOLY 32% Profit after Tax Rs.2.4 Bn % to Sales 12% Earning Per Share Rs. Per share 45.35 Equity Rs. 9.6 Bn GOLY 29% *IQVIA MAT DEC 2023
Slide 25: Key Performance Indicators Growth & Profits
Key Performance Indicators Growth & Profits Particulars 2023 2022 2021 2020 2019 Revenue PKR in “000”” 19,424,255 15,815,937 13,000,780 10,697,634 9,047,693 Revenue Growth % 22.81% 21.65% 21.53% 18.24% 20.59% Gross Profit % % 47.64% 50.77% 49.35% 47.87% 46.00% Operating Profit % % 16.70% 19.57% 17.2
Slide 26: Generating success year after year
Generating success year after year
Slide 27: Increasing Shareholder's Wealth
Increasing Shareholder’s Wealth ROA & ROE 32.47% 32.47% 31.67% 28.21% 25.04% 25.72% 25.72% 25.29% 25.93% 19.48% 21.42% 20.98% 19.25% 18.63% Return on Assets % Return on Equity % EPS, Dividend & Payout 66.15 51.23 45.35 45.62 43.17 42.13 37.31 40.77 34.66 34.66 36.55 30.86 25.37 24.53 Earnings Per Sh
Slide 28: Increasing Shareholder's Wealth
Increasing Shareholder’s Wealth Dividend Yield, PE Ratio & Market Value 700 627 599 20.00 600 504.6 540 537.2617.41 17.40 16.05 15.00 500 426.78 400 347.6513.70 11.13 10.00 300 9.36 9.36 200 5.95 5.00 100 3.70 3.19 3.74 2.50 2.42 2.34 0 - 2023 2022 2021 2020 2019 2018 2017 Market Value of Share Divi
Slide 29: Highnoon among Peers: Industry Analysis
Highnoon among Peers: Industry Analysis Market Cash Dividend Company Year End Revenue Gross Margin PAT EPS Net Margin Equity P/E P/S P/B ROE Capitalization Payout ABOT December'2023 45,055 55,475 21% 262 2.67 0% 18,237 172.36 0.81 2.47 Nil 1% AGP December'2023 19,687 13,858 44% 1,190 4.25 9% 10,853
Slide 30: Reinvestment to sustain & grow business
Reinvestment to sustain & grow business
Slide 31: Major expansion plan at QABP
Highnoon Laboratories is planning to embark on a major expansion plan. For this, the Company has acquired twelve (12) acres of land at QABP on Lahore- Islamabad Motorway. Being designated as a Special Economic Zone entity, the project envisages significant manufacturing and financial benefits.
Slide 32: Q & As
Highnoon Laboratories — Investor Presentation (April 2024) on 6ix